Search results for "59"

Campodeidae (Hexapoda: Diplura) from Kyrgyzstan, Central Asia, with the description of a remarkable new genus and species

2021

Samples collected in Central Asia, Kyrgyzstan, have revealed a hitherto unknown diversity of Campodeidae (Diplura) in soil and cave habitats, including a new genus and species, Kyrgyzstancampa sanare Sendra & Ferreira gen. et sp. nov., Turkmenocampa edaphica Sendra & Sánchez-García sp. nov. and a previously recognized soil-dwelling species, Campodea (Dicampa) catalana Denis, 1930. Kyrgyzstancampa sanare Sendra & Ferreira gen. et sp. nov. was collected in the deep zone of an interesting geological and cultural cave, Ak-Turpak Cave, located near the western margin of Kadamjay District, Batken Province. This genus belongs to the subfamily Campodeinae, sharing the morphology of the …

Asian cave-adapted diplurans, with the description of two new genera and four new species (Arthropoda, Hexapoda, Entognatha)

2021

Twenty-nine specimens of Diplura collected from eight caves in China and Myanmar contain two new genera, Hubeicampa Sendra & Lips gen. nov. and Mueggejapyx Sendra & Komerički gen. nov., as well as four new species, Anisuracampa ywangana Sendra & Komerički sp. nov., Hubeicampa melissa Sendra & Lips gen. et sp. nov., Pacificampa wudonghuii Sendra sp. nov. and Mueggejapyx brehieri Sendra & Komerički gen. et sp. nov. These cave-adapted taxa showcase an impressive diversity in morphological adaptation (troglomorphy) to cave ecosystems. Their sensorial equipment, setae and receptors in the cupuliform organ have unique forms (H. melissa gen. et sp. nov.), as well as the pretars…

In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.

2007

AbstractAn in vivo model of human CD20+ B-lymphoma was established in severe combined immunodeficiency mice to test the ability of human neutralizing miniantibodies to CD55 and CD59 (MB55 and MB59) to enhance the therapeutic effect of rituximab. The miniantibodies contained single-chain fragment variables and the hinge-CH2-CH3 domains of human IgG1. LCL2 cells were selected for the in vivo study among six B-lymphoma cell lines for their high susceptibility to rituximab-dependent complement-mediated killing enhanced by MB55 and MB59. The cells injected i.p. primarily colonized the liver and spleen, leading to the death of the animals within 30 to 40 days. Thirty percent of mice receiving bio…

Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherap…

2015

The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (CDC). We developed a novel strategy to enhance CDC using bispecific antibodies (bsAbs) that neutralize the C-regulators CD55 and CD59 to enhance C-mediated functions. Two bsAbs (MB20/55 and MB20/59) were designed to recognize CD20 on one side. The other side neutralizes CD55 or CD59. Analysis of CDC revealed that bsAbs could kill 4-25 times more cells than anti-CD20 recombinant antibody in cell lines or cells isolated from patients with chronic lymphocytic leukemia. The pharmacokinetics of the bsAbs was evaluate…

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1

2014

Human tumors develop multiple strategies to evade recognition and efficient suppression by the immune system. Therefore, a variety of immunotherapeutic strategies have been developed to reactivate and reorganize the human immune system. The recent development of new antibodies against immune check points may help to overcome the immune silencing induced by human tumors. Some of these antibodies have already been approved for treatment of various solid tumor entities. Interestingly, targeting antibodies may be combined with standard chemotherapy or radiation protocols. Furthermore, recent evidence indicates that intratumoral (it) or intravenous (iv) injections of replicative oncolytic viruse…

Expression and regulation by interferon-γ of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours

1999

The membrane-bound complement inhibitors CD46 (membrane cofactor protein), CD55 (decay-accelerating factor) and CD59 (protectin) protect tumour cells against lysis by activated complement. In this study, a total of 14 (3 gastric, 3 colonic and 8 pancreatic) gastrointestinal tumour cell lines were examined for the expression of CD46, CD55 and CD59 with respect to the regulatory efficacy of interferon-gamma (IFN-gamma). The effects of IFN-gamma on mRNA and protein expression levels of CD46, CD55 and CD59 were evaluated by Northern blot hybridisation, RT-PCR, flow cytometry and immunostaining. In unstimulated cell lines, CD46 and CD59 transcripts were expressed at comparable levels, whereas th…

Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor.

2012

Allosteric modulation of G-protein–coupled receptors represents a key goal of current pharmacology. In particular, endogenous allosteric modulators might represent important targets of interventions aimed at maximizing therapeutic efficacy and reducing side effects of drugs. Here we show that the anti-inflammatory lipid lipoxin A 4 is an endogenous allosteric enhancer of the CB 1 cannabinoid receptor. Lipoxin A 4 was detected in brain tissues, did not compete for the orthosteric binding site of the CB 1 receptor (vs. 3 H-SR141716A), and did not alter endocannabinoid metabolism (as opposed to URB597 and MAFP), but it enhanced affinity of anandamide at the CB1 receptor, thereby potentiating …

Sacrificios de el amor, y finezas de la lealtad en la gloriosa, plausible, y deseada aclamacion de ... Don Carlos III de las Hespañas, executada por…

1759

Caplletra grav., banda, vinyetes Sign.: A-D4, E2 Reclams

Sacrificios de el amor, y finezas de la lealtad en la gloriosa, plausible, y deseada aclamacion de ... Don Carlos III de las Hespañas, executada por …

Caplletra grav., banda, vinyetes Sign.: A-D4, E2 Reclams

Algunas reflexiones acerca de la stjue de 9 de julio de 2020 sobre los pactos novatorios en materia de cláusulas suelo

2021

The Sentence of the Court of Justice of the European Union of July 9, 2020 comes to answer the five questions that, in its preliminary question, the Court of First Instance and Instruction No. 3 of Teruel asks about the validity of the new agreements in the context of the floor clauses, establishing jurisprudential doctrine on this matter about which our Supreme Court had previously ruled in its Judgments of October 16, 2017, in the sense of considering the agreed floor clause null as a consequence of the novation agreement and, subsequently, those of April 11, 2018 and September 13, 2018 in the opposite direction, declaring that the novation agreement was valid. It is a long-awaited and in…